Table 1 Patient characteristics for the... | American Society of Hematology

Table 1

Patient characteristics for the total CLL population and the subpopulation initiating infused therapy

Characteristic/level	Total CLL population (n = 6433)		Infused therapy (n = 2040)
	Total CLL population (n = 6433)		Rituximab alone (n = 319)		Rituximab plus chemotherapy (n = 292)		Chemotherapy alone (n = 1429)
	No.	%	No.	%	No.	%	No.	%
Age, y
66-69	980	15.2	26	8.2	51	17.5	187	13.1
70-74	1414	22.0	76	23.8	75	25.7	374	26.2
75-79	1616	25.1	82	25.7	84	28.8	421	29.5
≥ 80	2423	37.7	135	42.3	82	28.1	447	31.3
Sex
Male	3488	54.2	173	54.2	169	57.9	872	61.0
Female	2945	45.8	146	45.8	123	42.1	557	39.0
Race/ethnicity
White	5678	88.3	287	90.0	268	91.8	1258	88.0
Black	326	5.1	12	3.8	24	8.2	82 51 38	5.7
Hispanic	182	2.8	20	6.3				3.6
Other	247	3.8						2.7
Year of diagnosis
1999	395	6.1	13	4.1	30	10.3	133 242	9.3
2000	871	13.5	33	10.3				16.9
2001	998	15.5	44	13.8	50	17.1	262	18.3
2002	997	15.5	44	13.8	53	18.2	239	16.7
2003	1094	17.0	54	16.9	65	22.3	232	16.2
2004	1108	17.2	55	17.2	52	17.8	201	14.1
2005	970	15.1	76	23.8	42	14.4	120	8.4
Stage
Not advanced	5081	79.0	103	32.3	66	22.6	351	24.6
Advanced	1352	21.0	216	67.7	226	77.4	1078	75.4
Anemia
Absent	5226	81.2	124	38.9	80	27.4	414	29.0
Present	1207	18.8	195	61.1	212	72.6	1015	71.0
Thrombocytopenia
Absent	6110	95.0	224	70.2	212	72.6	959	67.1
Present	323	5.0	95	29.8	80	27.4	470	32.9
Hemolytic anemia
Absent	6189	96.2	277	86.8	263	90.1	1322	92.5
Present	244	3.8	42	13.2	29	9.9	107	7.5
NCI Comorbidity Score
0	4102	63.8	190	59.6	201	68.8	979	68.5
1	1379	21.4	83	26.0	59	20.2	285	19.9
2	584	9.1	32	10.0	21	7.2	112	7.8
≥ 3	368	5.7	14	4.4	11	3.8	53	3.7
Metropolitan statistical area
Big metro	3374	52.4	179	56.1	163	55.8	736	51.5
Metro	1773	27.6	100	31.3	75	25.7	383	26.8
Urban	406	6.3	14	4.4	25	8.6	92	6.4
Less urban	713	11.1	26	8.2	29	9.9	171	12.0
Rural	167	2.6						3.3

Characteristic/level	Total CLL population (n = 6433)		Infused therapy (n = 2040)
	Total CLL population (n = 6433)		Rituximab alone (n = 319)		Rituximab plus chemotherapy (n = 292)		Chemotherapy alone (n = 1429)
	No.	%	No.	%	No.	%	No.	%
Age, y
66-69	980	15.2	26	8.2	51	17.5	187	13.1
70-74	1414	22.0	76	23.8	75	25.7	374	26.2
75-79	1616	25.1	82	25.7	84	28.8	421	29.5
≥ 80	2423	37.7	135	42.3	82	28.1	447	31.3
Sex
Male	3488	54.2	173	54.2	169	57.9	872	61.0
Female	2945	45.8	146	45.8	123	42.1	557	39.0
Race/ethnicity
White	5678	88.3	287	90.0	268	91.8	1258	88.0
Black	326	5.1	12	3.8	24	8.2	82 51 38	5.7
Hispanic	182	2.8	20	6.3				3.6
Other	247	3.8						2.7
Year of diagnosis
1999	395	6.1	13	4.1	30	10.3	133 242	9.3
2000	871	13.5	33	10.3				16.9
2001	998	15.5	44	13.8	50	17.1	262	18.3
2002	997	15.5	44	13.8	53	18.2	239	16.7
2003	1094	17.0	54	16.9	65	22.3	232	16.2
2004	1108	17.2	55	17.2	52	17.8	201	14.1
2005	970	15.1	76	23.8	42	14.4	120	8.4
Stage
Not advanced	5081	79.0	103	32.3	66	22.6	351	24.6
Advanced	1352	21.0	216	67.7	226	77.4	1078	75.4
Anemia
Absent	5226	81.2	124	38.9	80	27.4	414	29.0
Present	1207	18.8	195	61.1	212	72.6	1015	71.0
Thrombocytopenia
Absent	6110	95.0	224	70.2	212	72.6	959	67.1
Present	323	5.0	95	29.8	80	27.4	470	32.9
Hemolytic anemia
Absent	6189	96.2	277	86.8	263	90.1	1322	92.5
Present	244	3.8	42	13.2	29	9.9	107	7.5
NCI Comorbidity Score
0	4102	63.8	190	59.6	201	68.8	979	68.5
1	1379	21.4	83	26.0	59	20.2	285	19.9
2	584	9.1	32	10.0	21	7.2	112	7.8
≥ 3	368	5.7	14	4.4	11	3.8	53	3.7
Metropolitan statistical area
Big metro	3374	52.4	179	56.1	163	55.8	736	51.5
Metro	1773	27.6	100	31.3	75	25.7	383	26.8
Urban	406	6.3	14	4.4	25	8.6	92	6.4
Less urban	713	11.1	26	8.2	29	9.9	171	12.0
Rural	167	2.6						3.3

For subpopulation receiving infused therapy, age, anemia, hemolytic anemia, thrombocytopenia, and advanced stage (presence of anemia or thrombocytopenia) were defined as of the date of first infusion. Cells with counts < 11 are combined in compliance with the NCI data use agreement for small cell sizes.

View Large

This Feature Is Available To Subscribers Only